Kee H Wong1, Aleksandra Kuciejewska2, Mansour T A Sharabiani3, Brian Ng-Cheng-Hin2, Sonja Hoy2, Tara Hurley2, Joanna Rydon2, Lorna Grove4, Ana Santos4, Motoko Ryugenji4, Shreerang A Bhide5, Chris M Nutting6, Kevin J Harrington6, Kate L Newbold7. 1. Head and Neck Oncology Unit, Royal Marsden Hospital, Sutton, UK; The Institute of Cancer Research, London, UK. Electronic address: kee.wong@icr.ac.uk. 2. Head and Neck Oncology Unit, Royal Marsden Hospital, Sutton, UK. 3. Clinical Statistics Unit, Royal Marsden Hospital, Sutton, UK. 4. Head and Neck Oncology Unit, Royal Marsden Hospital, London, UK. 5. Head and Neck Oncology Unit, Royal Marsden Hospital, Sutton, UK; The Institute of Cancer Research, London, UK. 6. Head and Neck Oncology Unit, Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK. 7. Head and Neck Oncology Unit, Royal Marsden Hospital, Sutton, UK; The Institute of Cancer Research, London, UK. Electronic address: Kate.newbold@rmh.nhs.uk.
Abstract
PURPOSE: This phase III, non-blinded, parallel-group, randomised controlled study evaluated the efficacy of Caphosol mouthwash in the management of radiation-induced oral mucositis (OM) in patients with head and neck cancer (HNC) undergoing radical (chemo)radiotherapy. PATIENTS AND METHODS: Eligible patients were randomised at 1:1 to Caphosol plus standard oral care (intervention) or standard oral care alone (control), stratified by radiotherapy technique and use of concomitant chemotherapy. Patients in the intervention arm used Caphosol for 7weeks: 6weeks during and 1-week post-radiotherapy. The primary endpoint was the incidence of severe OM (CTCAE ⩾grade 3) during and up to week 8 post-radiotherapy. Secondary endpoints include pharyngeal mucositis, dysphagia, pain and quality of life. RESULTS: The intervention (n=108) and control (n=107) arms were well balanced in terms of patient demographics and treatment characteristics. Following exclusion of patients with missing data, 210 patients were available for analysis. The incidence of severe OM did not differ between the intervention and control arms (64.1% versus 65.4%, p=0.839). Similarly, no significant benefit was observed for other secondary endpoints. Overall, compliance with the recommended frequency of Caphosol was low. CONCLUSION: Caphosol did not reduce the incidence or duration of severe OM during and after radiotherapy in HNC.
PURPOSE: This phase III, non-blinded, parallel-group, randomised controlled study evaluated the efficacy of Caphosol mouthwash in the management of radiation-induced oral mucositis (OM) in patients with head and neck cancer (HNC) undergoing radical (chemo)radiotherapy. PATIENTS AND METHODS: Eligible patients were randomised at 1:1 to Caphosol plus standard oral care (intervention) or standard oral care alone (control), stratified by radiotherapy technique and use of concomitant chemotherapy. Patients in the intervention arm used Caphosol for 7weeks: 6weeks during and 1-week post-radiotherapy. The primary endpoint was the incidence of severe OM (CTCAE ⩾grade 3) during and up to week 8 post-radiotherapy. Secondary endpoints include pharyngeal mucositis, dysphagia, pain and quality of life. RESULTS: The intervention (n=108) and control (n=107) arms were well balanced in terms of patient demographics and treatment characteristics. Following exclusion of patients with missing data, 210 patients were available for analysis. The incidence of severe OM did not differ between the intervention and control arms (64.1% versus 65.4%, p=0.839). Similarly, no significant benefit was observed for other secondary endpoints. Overall, compliance with the recommended frequency of Caphosol was low. CONCLUSION: Caphosol did not reduce the incidence or duration of severe OM during and after radiotherapy in HNC.
Authors: Giuseppe Sanguineti; Maria Pia Sormani; Shanthi Marur; G Brandon Gunn; Nikhil Rao; Marco Cianchetti; Francesco Ricchetti; Todd McNutt; Binbin Wu; Arlene Forastiere Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-19 Impact factor: 7.038
Authors: Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg Journal: Radiother Oncol Date: 2003-03 Impact factor: 6.280
Authors: Liam Welsh; Rafal Panek; Dualta McQuaid; Alex Dunlop; Maria Schmidt; Angela Riddell; Dow-Mu Koh; Simon Doran; Iain Murray; Yong Du; Sue Chua; Vibeke Hansen; Kee H Wong; Jamie Dean; Sarah Gulliford; Shreerang Bhide; Martin O Leach; Christopher Nutting; Kevin Harrington; Kate Newbold Journal: Radiat Oncol Date: 2015-05-15 Impact factor: 3.481
Authors: Jamie A Dean; Liam C Welsh; Sarah L Gulliford; Kevin J Harrington; Christopher M Nutting Journal: Radiother Oncol Date: 2015-03-13 Impact factor: 6.280
Authors: Kranti A Mapuskar; Carryn M Anderson; Douglas R Spitz; Ines Batinic-Haberle; Bryan G Allen; Rebecca E Oberley-Deegan Journal: Semin Radiat Oncol Date: 2019-01 Impact factor: 5.934
Authors: Carryn M Anderson; Stephen T Sonis; Christopher M Lee; Douglas Adkins; Bryan G Allen; Wenqing Sun; Sanjiv S Agarwala; Madhavi L Venigalla; Yuhchyau Chen; Weining Zhen; Diane R Mould; Jon T Holmlund; Jeffrey M Brill; John M Buatti Journal: Int J Radiat Oncol Biol Phys Date: 2017-10-16 Impact factor: 7.038
Authors: Marika Cinausero; Giuseppe Aprile; Paola Ermacora; Debora Basile; Maria G Vitale; Valentina Fanotto; Giuseppe Parisi; Lorenzo Calvetti; Stephen T Sonis Journal: Front Pharmacol Date: 2017-06-08 Impact factor: 5.810
Authors: Carryn M Anderson; Christopher M Lee; Deborah P Saunders; Amarinthia Curtis; Neal Dunlap; Chaitali Nangia; Arielle S Lee; Sharon M Gordon; Philip Kovoor; Roberto Arevalo-Araujo; Voichita Bar-Ad; Abhinand Peddada; Kyle Colvett; Douglas Miller; Anshu K Jain; James Wheeler; Dukagjin Blakaj; Marcelo Bonomi; Sanjiv S Agarwala; Madhur Garg; Francis Worden; Jon Holmlund; Jeffrey M Brill; Matt Downs; Stephen T Sonis; Sanford Katz; John M Buatti Journal: J Clin Oncol Date: 2019-10-16 Impact factor: 44.544